Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study

Authors

  • Filomena Russo Dermatological Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy https://orcid.org/0000-0003-2780-7720
  • Natale Schettini Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy https://orcid.org/0000-0002-6693-766X
  • Giovanni Scaglione Bioinformatics Unit, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy https://orcid.org/0000-0001-5622-7843
  • Ester Del Duca Dermatologic Clinic, Sapienza University of Rome, Rome, Italy
  • Tommaso Bianchelli Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, Istituto Nazionale di Ricovero e Cura degli Anziani (INRCA)-IRCCS Hospital, Ancona, Italy.x
  • Niccolò Gori Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Flavia Margiotta Department of Dermatology, University of Pisa, Pisa, Italy; Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, Pisa, Italy
  • Laura Calabrese Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
  • Elettra Antonelli Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
  • Federica Giuliani Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy
  • Viviana Piras Dermatology Unit, AOU of Cagliari, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
  • Sabatino Pallotta Dermatological Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy
  • Chiara Bocchi Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
  • Edoardo Mortato Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
  • Camilla Chello Dermatologic Clinic, Sapienza University of Rome, Rome, Italy
  • Helena Gioacchini Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, Istituto Nazionale di Ricovero e Cura degli Anziani (INRCA)-IRCCS Hospital, Ancona, Italy.
  • Maria Cannizzaro U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Marco Romanelli Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, Pisa, Italy
  • Laura Lazzeri Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
  • Katharina Hansel Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
  • Paolo Amerio Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy
  • Laura Atzori Dermatology Unit, AOU of Cagliari, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
  • Marco Galluzzo Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; Dermatology Unit, Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0815

Keywords:

atopic dermatitis, flare, upadacitinib, disease control, atopic dermatitis control tool, minimal disease activity, therapeutic choice, patient reported outcomes

Abstract

Atopic dermatitisis a chronic skin disease that requires long-term monitoring, which can be assessed using Atopic Dermatitis Control Tool (ADCT). Achieving minimal disease activity is also becoming an important issue in the treatment of atopic dermatitis. We aimed to identify which minimal disease sctivity patient-reported outcomes most closely reflect ADCT-defined disease control. We conducted a multicentric, observational retrospective study in patients with moderate-to-severe atopic dermatitis treated with upadacitinib. Outcome measures were collected at different time points (Week 0, 4, 16, 32, 52). Longitudinal changes were assessed with the paired Wilcoxon signedrank test; cross-sectional ADCT–patient-reported outcomes associations were evaluated at each visit using Spearman rank correlation coefficient (ρ). A total of 212 were included. All outcomes improved significantly from Week 4 onwards (all p<0.001). An ADCT score<7 was reached by 84.6% of evaluable patients at Week 4 and 90.1% at Week 52. At each timepoint, ADCT showed the strongest correlation with POEM (ρ range: 0.64–0.64) compared to other minimal disease sctivity patient-reported outcomes. These findings indicate that, among the minimal disease sctivity patient-reported outcomes, POEM most closely reflects the patient’s perception of atopic dermatitis control assessed by ADCT. Larger prospective studies are warranted to confirm these preliminary observations.

Downloads

Download data is not yet available.

References

Russo F, Zink A, Magnolo N, Scala E, Scala E. Atopic Dermatitis and Climate: Environmental Stressors and Care Strategies. Dermatol Ther (Heidelb) 2025; 15: 3479–3493. DOI: https://doi.org/10.1007/s13555-025-01560-6

Russo F, Flori ML, Gola M, Milanesi N. Severe Adult Atopic Dermatitis: Clinical Challenges. Dermatitis 2020; 31: e48–e49. DOI: https://doi.org/10.1097/DER.0000000000000592

Merola JF, Weidinger S, Tan SY, Rahawi K, Gray C. Defining “Flares” in Atopic Dermatitis: A Narrative Review. Am J Clin Dermatol 2025; 26: 905–921. DOI: https://doi.org/10.1007/s40257-025-00966-4

Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367–376. DOI: https://doi.org/10.1080/03007995.2019.1699516

Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15. DOI: https://doi.org/10.1186/s12895-019-0095-3

Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol 2024; 38: 2139–2148. DOI: https://doi.org/10.1111/jdv.20229

Russo F, Cioppa V, Cartocci A, De Piano E, Taddeucci P, Lazzeri L, et al. Exploring the Relationship between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab. Dermatitis® 2023; 34: 440–444. DOI: https://doi.org/10.1089/derm.2022.0031

Cioppa V, Lazzeri L, Carraro A, De Piano E, Falcinelli F, Galluzzo M, et al. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab. Dermatitis 2024; 35: S107–S108. DOI: https://doi.org/10.1089/derm.2023.0052

Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The Atopic Dermatitis Control Tool: A High-Performance Tool for Optimal Support. Acta Derm Venereol 2021; 101: adv00618. DOI: https://doi.org/10.2340/actadv.v101.750

Kido-Nakahara M, Yokote G, Yoshida M, Furue M, Nakahara T. Atopic Dermatitis Control Tool (ADCT): A useful tool for self-evaluation in patients with atopic dermatitis. J Dermatol 2021; 48: 1951–1952. DOI: https://doi.org/10.1111/1346-8138.16176

Silverberg JI, Gooderham M, Wollenberg A, Pink AE, Ruiz Dasilva D, Kwatra SG, et al. Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis. Dermatol Ther (Heidelb) 2025; 15: 2255–2273. DOI: https://doi.org/10.1007/s13555-025-01469-0

Melgosa Ramos FJ, Guillén Climent S, Galarreta Pascual M, Martorell A, Matellanes Palacios M, Roca Ginés J, et al. Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter Cohort. Dermatol Ther (Heidelb) 2026; 16: 2213–2218. DOI: https://doi.org/10.1007/s13555-026-01683-4

Rodriguez-Sanna AI, Montero-Vilchez C, Moreno-Suarez FG, Garrido-Colmenero C, Aceituno-Madera P, Arias-Santiago S, et al. Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity. Dermatitis 2025: derm20240553. DOI: https://doi.org/10.1089/derm.2024.0553

Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2). Dermatol Ther (Heidelb) 2025; 15: 2583–2594. DOI: https://doi.org/10.1007/s13555-025-01485-0

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140: 1513–1519. DOI: https://doi.org/10.1001/archderm.140.12.1513

Downloads

Additional Files

Published

2026-11-02

How to Cite

Russo, F., Schettini, N., Scaglione, G., Del Duca, E., Bianchelli, T., Gori, N., … Galluzzo, M. (2026). Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0815

Issue

Vol. 106 (2026)

Section

Articles

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC